BCAL Diagnostics Limited (AU:BDX) has released an update.
BCAL Diagnostics Limited (BDX) has stated in response to the ASX Compliance Price Query that there is no undisclosed information that could explain recent trading activity in its securities. The company is currently in the process of a capital raise through share placement, pending board approval and finalization. BDX also observed an unrelated surge in shares of CLEO Diagnostics, which might have influenced BDX’s share activity, though this remains speculative.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.
